← 홈

Antibody · 위암

70개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 70개
AntibodystaleShanghai JMT-Bio Inc.Phase 2

Pembolizumab (Pembolizumab)

HER2-positive Gastric Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleXijing HospitalPreclinical

Penpulimab combination with anlotinib and chemotherapy (Penpulimab combination with anlotinib and chemotherapy)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital w…Phase 2

Iparomlimab/Tuvonralimab (QL1706, QL1706 (Iparomlimab/Tuvonralimab))

Gastric Cancer Stage III · Gastric Cancer Stage III

#GastricCancerStageIII#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Bevacizumab (QLS5132; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Olaparib; Bevacizumab (QLS5132; Olaparib; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

QLS5132; Platinum; Bevacizumab (QLS5132; Platinum; Bevacizumab)

Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleImugene LimitedPhase 2

Ramucirumab plus Paclitaxel (Ramucirumab plus Paclitaxel)

Gastric Cancer; Cancer of Stomach · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleHenan Cancer HospitalPhase 2

trastuzumab (Herceptin, SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInnoventPhase 2

Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib (Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib)

Gastric (Stomach) Cancer · Gastric (Stomach) Cancer

#GastricStomachCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleRochePreclinical

trastuzumab (Herceptin, TRASTUZUMAB BS)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 85.7%임상시험 1상태 ACTIVE
AntibodystaleBeiGenePhase 3

Tislelizumab+Oxaliplatin+Capecitabine (Tislelizumab+Oxaliplatin+Capecitabine)

Gastric Carcinoma · Gastric Carcinoma

#GastricCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 1

trastuzumab (Herceptin, Tislelizumab，atezolizumab or Trastuzumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab + NK cells)

Breast Cancer; Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

pembrolizumab (Keytruda, Capecitabine Tablets + Oxaliplatin, Trastuzumab + Pembrolizumab + CAPOX, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin))

Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · Patients With Unresectable Locally Advan

#PatientsWithUnresectableLocallyA#Antibody#Phase3#항체#면역항체+2
효능 ORR 80%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab + Ramucirumab + Paclitaxel)

Recurrent/Metastatic Gastric Cancer · Recurrent/Metastatic Gastric Cancer

#RecurrentMetastaticGastricCancer#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

trastuzumab (Herceptin, Trastuzumab Rezatecan and Retlirafusp alfa)

Gastric or Gastroesophageal Junction Adenocarcinoma · Gastric or Gastroesophageal Junction Ade

#GastricorGastroesophagealJunctio#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab+Capecitabine+Oxaliplatin)

Gastric Cancer · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE

3 / 4 페이지

← 이전다음 →